8-K: NewAmsterdam Pharma CAO Louise Kooij to Depart
Executive Departure
NewAmsterdam Pharma Company N.V. announced the departure of Chief Accounting Officer Louise Kooij effective August 31, 2026.
Summary
- Chief Accounting Officer Louise Kooij will step down from her role effective August 31, 2026.
- The company entered into a separation agreement on April 24, 2026.
- Compensation includes 12 months of base salary, a pro-rated 2026 annual bonus, and payment for accrued vacation time.
- Equity awards will see extended vesting through January 10, 2027, with vested options exercisable until February 10, 2027.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative update regarding a planned executive departure with no immediate impact on the company's core business strategy.
Positives
- The separation agreement includes standard restrictive covenants such as non-compete, non-disparagement, and confidentiality clauses to protect company interests.
Negatives
- The departure of a Chief Accounting Officer creates a temporary leadership gap in the finance department.
Risks
- Potential disruption to financial reporting processes during the transition period leading up to the August 31, 2026, departure date.
Future Outlook
The company has not provided specific guidance regarding the search for a successor or changes to financial reporting structures following the departure.
Industry Context
StockSavvy.ai notes that executive turnover in the C-suite, particularly in accounting roles, is a standard corporate event, though it requires monitoring to ensure continuity in financial oversight and internal controls.
Comparison to Industry Standards
- The separation terms, including salary continuation and equity vesting extensions, are consistent with standard executive severance packages for publicly traded biotech firms.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Accounting Officer | Louise Kooij | Not announced | 2026-08-31 | Mutual agreement |
Stakeholder Impact
- Shareholders should monitor the announcement of a successor to ensure stability in financial reporting.
Next Steps
- Filing of the full Separation Agreement with the Quarterly Report on Form 10-Q for the quarter ending June 30, 2026.
Key Dates
| Date | Description |
|---|---|
| 2026-04-20 | Date of agreement regarding the end of employment. |
| 2026-04-24 | Date of execution of the formal separation agreement. |
| 2026-08-31 | Effective date of separation for Louise Kooij. |
| 2027-01-10 | Extended vesting date for stock options and RSUs. |
| 2027-02-10 | Expiration date for exercise of vested stock options. |
Keywords
NewAmsterdam Pharma, NAMS, Chief Accounting Officer, Executive Departure, Corporate Governance, Separation Agreement
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.